Fast Facts:
• Up to 20% of patients with DM2 have evidence of retinopathy at the time of diagnosis.
• Only about 60% of people with DM in the U.S. receive the recommended yearly screening and our clinics at Texas Tech Physicians of El Paso are even lower than this.
• In order to better serve our patients at TTP El Paso, we are providing education to patients and providers as well as making retinal cameras available in selected clinics.

Objectives: Upon completion of this session, the participant should be able to:
• Explain the pathophysiology of diabetic retinopathy.
• Reinforce the importance of early screening and treatment as needed.
• Describe treatment strategies for diabetic retinopathy.
• Describe importance of early referral and treatment for age-related macular degeneration and retinal vein occlusion.

Accreditation: The Texas Tech University Health Sciences Center El Paso Paul L. Foster School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The Texas Tech University Health Sciences Center El Paso Paul L. Foster School of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure:
It is the policy and practice of the Texas Tech University Health Sciences Center El Paso Paul L. Foster School of Medicine’s Office of Continuing Medical Education (CME) to resolve all potential conflicts of interest prior to the activity.

None of the planners or speakers have relevant financial relationships to disclose except for Michael Maldonado, O.D., M.B.A., who is part of a speaker’s bureau for Eyevance Pharmaceuticals. This relevant financial relationship has been mitigated.